The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Open accessAbstract
The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported.1 , 2 This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed. The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (with evolocumab, a fully human monoclonal PCSK9 antibody) in 27 564 patients with atherosclerotic cardiovascular disease (ASCVD) was the first to be completed.1 The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE)-1 and -2 trials were, however, stopped early following termination of bococizumab development due to effects specific to this antibody (Box 1).2 , 3 In FOURIER, lowering of low-density lipoprotein cholesterol (LDL-C) levels by 59% (from 2.4 mmol/L to 0.78 mmol/L) significantly reduced the risk of major cardiovascular events (absolute event rates 9.8% vs. 11.3% on placebo over 2.2 years, relative risk reduction of 15%). The clinical benefit of PCSK9 inhibitor treatment was due to reduction of nonfatal events, largely driven by reduction in myocardial infarction (MI) and coronary revascularization. This benefit was generally consistent across all major patient subgroups, including age, sex, and type of clinical presentation of ASCVD [coronary artery disease (CAD) with history of MI, ischaemic stroke and symptomatic peripheral arterial disease (PAD)], and accrued over time.1 Compared with the Cholesterol Treatment Trialists’ (CTT) Collaboration for cardiovascular benefit per mmol/L reduction in LDL-C, which is based on average response over 5 years on statin therapy, the observed benefit in FOURIER was shown to fall below the regression line. When adjusted for duration of treatment, however, as the benefit of a cholesterol lowering therapy in the first year of treatment is less than in the following years, the results from FOURIER were superimposable with those observed with statin therapy (Figure 1).4 Evidence from studies involving variants in the genes encoding PCSK9 and 3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase provides further support for the concept that a similar risk reduction per unit LDL-C reduction is to be expected.5
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“discrepancies between biomarker and drug-target 97 can be informative for elucidating the 502 aetiology of disease and with it, shed light on new approaches to treating and preventing 503 disease.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [97]
In the citing paper
“colchicine 53 and icosapent ethyl 97 have both demonstrated efficacy in reduction of CVD in 494 recent large-scale phase III trials, however the precise mechanisms by which these drugs act, 495 i.e. the causal intermediaries, remains elusive.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Self-citationEuropean Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationPedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Cited by
Sorted by citations
Items 101–200 of 200
Packard, C. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1003-x · Cited by 13
New prospects for PCSK9 inhibition?
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy147 · Cited by 12
Self-citationIs There a Need to Revise Goals in the Management of Dyslipidemias?
Sinning, D., & Landmesser, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1128-6 · Cited by 12
Self-citation2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.213 · Cited by 12
Snel, M., & Descamps, O. S. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2256182 · Cited by 10
Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease
Catapano, A. L., Tokgözoğlu, L. S., Silva, A. M. E., & Bruckert, É. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100002 · Cited by 11
Self-citationStatus of PCSK9 Monoclonal Antibodies in Australia
Scherer, D. J., Nelson, A. J., O’Brien, R. C., Kostner, K., Hare, D. L., Colquhoun, D. M., Barter, P. J., Aylward, P. E., Nicholls, S. J., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.04.014 · Cited by 10
Crea, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab295 · Cited by 10
Chlebus, K., Cybulska, B., Dobrowolski, P., Romanowska-Kocejko, M., Żarczyńska-Buchowiecka, M., Gilis-Malinowska, N., Stróżyk, A., Borowiec-Wolna, J., Pajkowski, M., Bobrowska, B., et al. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0003 · Cited by 9
Vohnout, B., Fábryová, Ľ., Klabník, A., Kadurová, M., Bálinth, K., Kozárová, M., Bugáňová, I., Sirotiaková, J., & Rašlová, K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.857 · Cited by 9
Statement for Appropriate Clinical Use of PCSK9 Inhibitors
Nohara, A., Ohmura, H., Okazaki, H., Ogura, M., Kitagawa, K., Koseki, M., Sato, K., Tsukamoto, K., Yamashita, S., & On behalf of the Japan Atherosclerosis Society Working Group on Statement for Appropriate Use of PCSK9 Inhibitors (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.45229 · Cited by 9
How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner
Cardoso, R. N., Blumenthal, R. S., Kopecky, S. L., López-Jiménez, F. A., & Martin, S. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.011 · Cited by 10
Colivicchi, F., Fusco, S. A. D., Gulizia, M. M., Luca, L. D., Geraci, G., Nardi, F., Rossini, R., Gonzini, L., Scicchitano, P., Caldarola, P., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001132 · Cited by 9
The challenge of peripheral arterial disease: How do we improve outcome?
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.031 · Cited by 9
Self-citationZhang, Z., Yang, R., Zhu, J., Yang, X., Luo, H., Wang, H., & Luo, X. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8498 · Cited by 8
de Isla, L. P., Ray, K. K., Watts, G. F., Santos, R. D., Rodrigo Alonso, K., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., Badimón, L., Catapano, A. L., & Mata, P. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.003 · Cited by 8
Self-citationMickiewicz, A., Marlęga-Linert, J., Kuchta, A., Bachorski, W., Ćwiklińska, A., Raczak, G., Gruchała, M., & Fijałkowski, M. (2021) · Journal of Clinical Apheresis · doi:10.1002/jca.21872 · Cited by 8
Khatib, R., Angus, N. J., Hansen, T. B., Lambrinou, E., Vellone, E., Khan, M., & Lee, G. (2021) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvab106 · Cited by 8
PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility
Raal, F. J., CHILTON, R. J., Ranjith, N., Rambiritch, V., Leisegang, R. F., Ebrahim, I. O., van Tonder, A., Shunmoogam, N., Bouharati, C., Musa, M. G., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213114138 · Cited by 8
Alirocumab as add-on therapy to statins: current evidence and clinical potential
Auer, J., & Berent, R. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718775352 · Cited by 7
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
Masson, W. M., Huerin, M. S., Lobo, M., Masson, G., Molinero, G. B., Nemec, M., Boccadoro, M., Romero, C. P., Micali, G., & Siniawski, D. A. (2020) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd7010006 · Cited by 7
2022 Consensus statement on the management of familial hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., on behalf of Task Force Team for Familial Hypercholesterolemia, & Korean Society of Lipid and Atherosclerosis (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.121 · Cited by 10
Guijarro, C., & Camafort, M. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.05.010 · Cited by 8
Hypercholesterolaemia and coronary artery disease: A silent killer with several faces
Ferrières, J. (2018) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2018.11.007 · Cited by 7
Practical guide for the use of PCSK9 inhibitors in Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.07.004 · Cited by 7
Davis, L. E., & Pogge, E. K. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00399-6 · Cited by 6
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 6
Schettler, V. J. J., Muellendorff, F., Schettler, E., Platzer, C., Norkauer, S., Julius, U., & Neumann, C. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12792 · Cited by 6
Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ?
Sabouret, P. F., Farnier, M., & Puymirat, É. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.01.009 · Cited by 6
Self-citationLi, L.-Y., Chen, S., Li, F., Wu, Z., Shen, Y. H., Ding, F., Wang, X., Shen, W., Chen, Q., Dai, Y., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02694-7 · Cited by 5
Guijarro, C., & Camafort, M. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.05.005 · Cited by 5
Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
Steffens, D., Bramlage, P., Müller, J., Dorn, C., Paar, W. D., Scheeff, C., Kašner, M., & Rauch‐Kröhnert, U. (2021) · Open Heart · doi:10.1136/openhrt-2021-001572 · Cited by 5
Real-World Use of Alirocumab: Experience from a Large Healthcare Provider
Elis, A., Cohen, C. M., & Chodick, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031084 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Self-citationTomoi, Y., Yamaji, K., Soga, Y., Hiramori, S., & Andò, K. (2019) · Journal of Endovascular Therapy · doi:10.1177/1526602819836382 · Cited by 4
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13637 · Cited by 4
Datos de vida real en el uso de IPCSK9
Zúñiga, M. Á. L., Toro, M. A. M., & Medina, M. D. D. (2019) · Revista Clínica Española · doi:10.1016/j.rce.2019.06.001 · Cited by 4
Ложкина, Н. Г., Gushchina, O. I., Evdokimova, N. E., & Parkhomenko, О. M. (2021) · Медико-фармацевтический журнал «Пульс» · doi:10.26787/nydha-2686-6838-2021-23-3-95-102 · Cited by 4
Gil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.11.014 · Cited by 4
25 years of lipid-lowering therapy: secular trends in therapy of coronary patients
Ratz, M., Vogel, J. B., Kuehrer, H., Säly, C., Mündlein, A., Vonbank, A., MADER, A., Fraunberger, P., Leiherer, A., & Drexel, H. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02365-x · Cited by 4
Vavlukis, M., & Vavlukis, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82520 · Cited by 4
Derosa, G., Maffioli, P., D’Angelo, A., Girola, A., Colombo, E., Fiorenza, A. M., Ceballos-Macías, J. J., Sanchez, C. L., Raddino, R., Pasini, G. F., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001237 · Cited by 4
Blom, D. J., Breedt, J., Burgess, L. J., Ebrahim, I. O., Ellis, G., Soma, P., van der Walt, E., Naidoo, P., van Tonder, A., & Raal, F. J. (2019) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2019-039 · Cited by 4
Lipids and lipid lowering: current management with statins and PCSK9 inhibitors
Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy187 · Cited by 3
Self-citationGil-Núñez, A., Masjuán, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F. F., Arenillas, J. F., & Palacio, E. (2021) · Neurología · doi:10.1016/j.nrl.2020.11.006 · Cited by 3
Coronary angiotomography in patients with acute coronary syndrome without ST elevation
Chapman, I., Kuschnir, P., Sciancalepore, A., Conde, D. G., Furmento, J., & Costabel, J. P. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102452 · Cited by 3
Sechs Maßnahmen bei Statin-assoziierten Muskelschmerzen
Klose, G. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-0090-3 · Cited by 3
Hovingh, G. K., Guyton, J. R., Langslet, G., Dufour, R., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Farnier, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.08.011 · Cited by 3
Self-citationSquaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
Watts, G. F., & Norman, R. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.003 · Cited by 3
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
Abdalwahab, A., Al‐Atta, A., Zaman, A., & Alkhalil, M. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.472 · Cited by 2
Sudano, I., Mach, F., Moccetti, T., Burkard, T., Fahe, C., Delabays, A., Rickli, H., Keller, P., Dopheide, J. F., Bodenmann, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.953040 · Cited by 2
Nouvelles recommandations sur la prise en charge des dyslipidémies
Farnier, M. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.09.002 · Cited by 2
Self-citationThe 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
Thanassoulis, G., Grégoire, J. C., & Pearson, G. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.03.003 · Cited by 2
Dyslipidemia and Chronic Kidney Disease
Reule, S. A., Ishani, A., & Goldsmith, D. J. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00066-8 · Cited by 2
Tankova, T. I., Elenkova, A. P., Robeva, R. N., Dimova, R. B., Borissovа, A.-M., Olszewski, A., Lachev, V. I., & Petkova, R. T. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00748-2 · Cited by 2
PHARMACOECONOMICS OF TREATMENT PATIENTS WITH HIGH LEVEL HYPERCHOLESTEROLEMIA
Фатенков, О. В., Panisheva, Y. A., Анатольевна, Г. М., & Халитович, С. И. (2019) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2019-4-1-26-31 · Cited by 2
Stock, J. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.013 · Cited by 2
Self-citationButty, A., Gencer, B., Koskinas, K. C., Carballo, D., Räber, L., Klingenberg, R., Matter, C. M., Lüscher, T. F., Windecker, S., Müller, O., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.012 · Cited by 2
Self-citationPintarić, H. (2020) · Acta Clinica Croatica · doi:10.20471/acc.2020.59.04.10 · Cited by 2
Chapman, M. J., Thérond, P., & Meikle, P. J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109050 · Cited by 1
Self-citationPCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?
Ward, N. C., & Watts, G. F. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.015 · Cited by 1
Therapie der diabetischen Dyslipidämie
Brandts, J., & Lebherz, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0362-7 · Cited by 1
Główczyńska, R., Hus, A., Raszeja‐Wyszomirska, J., & Opolski, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy361 · Cited by 1
Guia prático para a utilização dos inibidores da PCSK9 em Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.05.005 · Cited by 6
Sinning, D., & Landmesser, U. (2018) · Kardiologie up2date · doi:10.1055/a-0509-2676
Self-citation2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Korean Journal of Medicine · doi:10.3904/kjm.2022.97.6.339 · Cited by 1
Ахмеджанов, Н. М., Vezikova, N. N., Voevoda, M. I., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Владиславович, Е. М., IuA, K., Кашталап, В. В., Konovalov, G. A., et al. (2019) · Kardiologiia · doi:10.18087/cardio.n308 · Cited by 1
Attaining cholesterol goals: will aiming for lower targets improve the score?
Leong, I.-L., Tomlinson, B., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1411341 · Cited by 1
Barradas‐Pires, A., Alcazar, M. D., Martínez‐Rubio, A., & Dimopoulos, K. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa140 · Cited by 1
Masana, L., Ibarretxe, D., Rodríguez-Borjabad, C., Plana, N., Valdivielso, P., Pedro‐Botet, J., Civeira, F., López‐Miranda, J., Guijarro, C., Mostaza, J. M., et al. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100006 · Cited by 1
RetractedNuevos enfoques farmacológicos para el riesgo cardiovascular
Mazón‐Ramos, P. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2017.12.015
The highs and lows of cardiovascular disease prevention
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.005
Self-citationThe year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Self-citationNew pharmacological approaches for cardiovascular risk
Mazón‐Ramos, P. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.12.035
Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients
Mantsiou, C. D., & Τζιόμαλος, Κ. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1510224
Vallejo‐Vaz, A. J. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.13.1.ge3
Hemmung der Proproteinkonvertase Subtilisin/Kexin Typ 9
Müller‐Wieland, D., Brandts, J., Marx, N., & Schütt, K. S. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0394-z
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-124740
Gesundheitsökonomische Aspekte der Verschreibung von PCSK9-Hemmern
Dressel, A., Schmidt, B., Schmidt, N., Laufs, U., Fath, F., Grammer, T. B., & März, W. (2018) · CardioVasc · doi:10.1007/s15027-018-1480-2
Prävention kardiovaskulärer Erkrankungen durch medikamentöse LDL-Cholesterin-Senkung
Lebherz, C. (2018) · Kardiologie up2date · doi:10.1055/a-0662-1062
Navarro, A. L. M., Enríquez, A. J., Serrano, J. A., Lamarca, Y. B., Abad, D., & Orna, J. A. G. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.01.018
Medikamentöse Therapie von Fettstoffwechselstörungen bei Patienten mit Typ-2-Diabetes
Müller‐Wieland, D., & Parhofer, K. G. (2019) · Gefäßmedizin Scan - Zeitschrift für Angiologie Gefäßchirurgie diagnostische und interventionelle Radiologie · doi:10.1055/a-0858-3922
Interdose lipid profile evaluation of PCSK9i in real life
Zúñiga, M. Á. L., Toro, M. A. M., & Medina, M. D. D. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.06.001
Navarro, A. L. M., Enríquez, A. J., Serrano, J. A. M., Lamarca, Y. B., Abad, D., & Orna, J. A. G. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.08.002
Is there LDL extability between two doses in patients using iPCSK9?
Zúñiga, M. Á. L., Toro, M. A. M., & Medina, M. D. D. (2019) · ACTUALIDAD MEDICA · doi:10.15568/am.2019.807.or04
Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa130
Self-citationParhofer, K. G. (2020) · Der Internist · doi:10.1007/s00108-020-00799-9
Diabetes and cardiovascular risk
Karásek, D. (2018) · Interní medicína pro praxi · doi:10.36290/int.2018.011
Simerzin, V. V., Александровна, К. М., & Вячеславович, Г. А. (2019) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2019-4-1-20-25
Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Dopheide, J. F., Adam, L., Wiedmer, S., Kaspar, M., Silbernagel, G., Baumgärtner, I., & Drexel, H. (2021) · Current Vascular Pharmacology · doi:10.2174/1570161119666210111123621
Li, L. Y., Shen, Y. H., Chen, S., Li, F. F., Wu, Z. M., Ding, F. H., Wang, X. Q., Shen, W. F., Chen, Q., Dai, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1230680/v1
Gómez-Álvarez, E., Chauvet, A. A., & Hernández‐Flores, K. R. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100801
ПРОГРЕССИРУЮЩИЙ АТЕРОСКЛЕРОЗ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА: ФАКТОРЫ РИСКА, ТЕЧЕНИЕ И ПРОГНОЗ
ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины» (ФИЦ ФТМ), Г. Н., Геннадьевна, Л. Н., Пархоменко, О. М., 1», Г. Н. «. К. Б. №., Максимов, В. Н., наук», Ф. «.-И. И. Т. И. П. М. (. –. Ф. Ф. «. И. Ц. И. Ц. И. Г. С. О. Р. А., Voevoda, M. I., ФТМ), Ф. «. И. Ц. Ф. И. Т. М. (., Иосифович, Б. Ю., & 1», Г. Н. «. К. Б. №. (2023) · ICSP «NEW SCIENCE» eBooks · doi:10.46916/09032023-978-5-00174-895-3
Barradas‐Pires, A., Blanco, L. M., & Alcazar, M. D. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.06.004
PCSK9 inhibitors in real life—Cardiometabolic risk management in dyslipidemic patients in Vienna
Ferch, M., Sert, C., Fellinger, P., Kautzky‐Willer, A., & Winhofer-Stöckl, Y. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02402-9
The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms
He, Z., Lu, M., Ding, Z., Chen, Z., Guan, T., Li, Z., Zhou, C., Tao, H., Cheng, G., & Liu, Y. (2025) · American Journal of Molecular Biology · doi:10.4236/ajmb.2025.151009
Sarkies, M., Manski-Nankervis, J.-A. E., Srinivasan, S., Raffoul, N., Mazariego, C. G., Carrigan, A., Hemmert, C., GLENN, N., SULLIVAN, D. R., Radford, J. C., et al. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.013
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
Metadata
- Authors
- Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Lüscher, T. F., Piepoli, M. F., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L., Pinto, F., Tokgözoğlu, L., Bax, J. J., & Catapano, A. L.
- Affiliations
- German Centre for Cardiovascular Research (DE)
- Inserm (FR)
- European Atherosclerosis Society (SE)
- Sorbonne Université (FR)
- Ninewells Hospital (GB)
- Sahlgrenska University Hospital (SE)
- CHU Dijon Bourgogne (FR)
- Wayne State University (US)
- University Hospital in Halle (DE)
- Trinity College Dublin (IE)
- University Medical Center Utrecht (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Zurich (CH)
- Guglielmo da Saliceto Hospital (IT)
- Imperial College London (GB)
- University Hospital of Bern (CH)
- Department of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
- University of Lisbon (PT)
- Hacettepe University (TR)
- Leiden University Medical Center (NL)
- University of Milan (IT)
- Corresponding author
- Landmesser, Ulf
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-16
- Volume
- 39
- Issue
- 14
- Pages
- 1131-1143
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2766232664
- Cited by
- 200
- References
- 57
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 5 · 2023: 7 · 2022: 12 · 2021: 26 · 2020: 30 · 2019: 62 · 2018: 50 · 2017: 4
- FWCI
- 40.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Edwards Lifesciences
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Kowa Company
- Mylan
- Servier
- Esperion Therapeutics
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- PCSK9 inhibitors, atherosclerotic cardiovascular disease, familial hypercholesterolemia, evolocumab, FOURIER trial, LDL cholesterol lowering, cardiovascular outcomes, clinical decision algorithm, treatment monitoring, bococizumab
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Coronary Artery Disease, Female, Humans, Hyperlipoproteinemia Type II, Male, Middle Aged, Advisory Committees, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
